CEL-SCI Corp (CVM)

0.47
0.02 4.40
AMEX : Health Care
Prev Close 0.46
Open 0.47
Day Low/High 0.47 / 0.47
52 Wk Low/High 0.36 / 0.80
Volume 33.52K
Avg Volume 288.70K
Exchange AMEX
Shares Outstanding 134.92M
Market Cap 64.76M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of May it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer immunotherapy company, announced today that it will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City...

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has closed its previously announced registered direct offering with a single healthcare dedicated institutional investor.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 10 million shares of its common stock and...

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2016.

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of April it has enrolled 41 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its CEO, Geert Kersten, was recently interviewed on The RedChip Money Report television program.

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of March it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of February it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress In A New Video Interview

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress In A New Video Interview

CEL-SCI Corporation (NYSE MKT:CVM) announced today that a new video interview with Geert Kersten, Chief Executive Officer, is available for viewing.

CEL-SCI CEO Geert Kersten Was A Featured Guest On Fox Business' Making Money With Charles Payne

CEL-SCI CEO Geert Kersten Was A Featured Guest On Fox Business' Making Money With Charles Payne

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its Chief Executive Officer Geert Kersten was a guest on Fox Business' Making Money with Charles Payne.

CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2015.

CEL-SCI To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

CEL-SCI To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

CEL-SCI Corporation (NYSE MKT: CVM) announced today that Geert Kersten, Chief Executive officer, will provide a company overview at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on...

CEL-SCI To Present At 18th Annual BIO CEO & Investor Conference

CEL-SCI To Present At 18th Annual BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 18 th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 11:00 a.

CEL-SCI Reports Monthly Patient Enrollment In January For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In January For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI's Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

CEL-SCI's Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific Officer, Eyal Talor, Ph.

CEL-SCI Corporation To Present At The Noble Financial Capital Markets' 12th Annual Investor Conference

CEL-SCI Corporation To Present At The Noble Financial Capital Markets' 12th Annual Investor Conference

CEL-SCI Corporation (NYSE MKT: CVM), a Phase 3 cancer immunotherapy company, today announced that its Chief Executive Officer, Geert Kersten, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual...

CEL-SCI Corporation Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016

CEL-SCI Corporation Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016

The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders: Dear Fellow Shareholders: As CEL-SCI shareholders most of you have been following the progress in our...

CEL-SCI Reports Record Year For Patient Enrollment With 75% Increase In Its Global Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Year For Patient Enrollment With 75% Increase In Its Global Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte...

CEL-SCI Reports Fiscal 2015 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2015 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") reported financial results today for the fiscal year ended September 30, 2015.

CEL-SCI's CEO Presentation Available On Company Website

CEL-SCI's CEO Presentation Available On Company Website

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced that the presentation made by Geert Kersten, Chief Executive Officer of CEL-SCI, at the 8 th annual LD Micro Main Event on Thursday,...

CEL-SCI Reports Monthly Patient Enrollment In November For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In November For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in the month of November it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Is Granted A New European Patent On Its Phase 3 Investigational Cancer Immunotherapy Multikine

CEL-SCI Is Granted A New European Patent On Its Phase 3 Investigational Cancer Immunotherapy Multikine

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") announces that it has been granted a European patent on Multikine (Leukocyte Interleukin, Injection), its investigational Phase 3 cancer immunotherapy.

CEL-SCI's Rheumatoid Arthritis Vaccine Selected For Commercialization & Program Niche Analysis Plan By U.S. National Institutes Of Health

CEL-SCI's Rheumatoid Arthritis Vaccine Selected For Commercialization & Program Niche Analysis Plan By U.S. National Institutes Of Health

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that its investigational LEAPS rheumatoid arthritis vaccine candidate has been accepted for a new program of technology...

CEL-SCI Reports Record Monthly Patient Enrollment In October For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Monthly Patient Enrollment In October For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in the month of October it has enrolled 38 patients in the ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Announces Closing Of Public Offering For Gross Proceeds Of $11.5 Million

CEL-SCI Announces Closing Of Public Offering For Gross Proceeds Of $11.5 Million

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that it has closed a best efforts offering of 17,223,248 shares of common stock and 17,223,248 warrants to purchase shares of common stock.

CEL-SCI Prices Public Offering For Up To $12 Million

CEL-SCI Prices Public Offering For Up To $12 Million

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that it has priced a best efforts offering of common stock and warrants at a combined price of $0.

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that it has commenced an offering of common stock and warrants.